Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size to Reach $11.4 Billion by 2035

Global dipeptidyl Peptidase 4 (DPP-4) Inhibitors market size reached $8.1 billion in 2025 and is projected to expand to $11.4 billion by 2035, growing at a CAGR of 3.5% during the forecast period (2026–2035). Market growth is supported by rising prevalence of type 2 diabetes, aging populations, and increased diagnosis rates.

Browse the full report description of “Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Size, Share & Trends Analysis Report by Drug Type (Sitagliptin, Vildagliptin, Saxagliptin, Linagliptin, Gemigliptin, Anagliptin, Teneligliptin, and Others), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/dipeptidyl-peptidase-4-inhibitors-market

Key Market Drivers

• Increasing global incidence of type 2 diabetes requiring long-term pharmacological management.
  • Growing elderly population with higher susceptibility to metabolic disorders.
  • Preference for oral antidiabetic therapies with low hypoglycemia risk.
  • Expanding healthcare access and diabetes screening programs.
  • Inclusion of DPP-4 inhibitors in clinical treatment guidelines.

Regional Analysis

Asia-Pacific accounts for a substantial share of the market due to high diabetes prevalence and large patient populations. China represents one of the largest affected populations globally, with government-led chronic disease management programs supporting treatment access. India is also experiencing rising demand driven by increasing diabetes incidence, urban lifestyle changes, and expanding availability of oral antidiabetic drugs through public and private healthcare systems.

North America maintains steady demand supported by advanced healthcare infrastructure and widespread screening initiatives. The US market benefits from established reimbursement systems and high diagnosis rates for type 2 diabetes, encouraging consistent prescription volumes of oral therapies. Clinical practice guidelines emphasizing individualized treatment options further support the use of DPP-4 inhibitors for specific patient groups.

Europe shows moderate growth influenced by aging demographics and structured disease management programs. The UK healthcare system supports diabetes care through national screening initiatives and long-term treatment pathways. Regulatory oversight by European authorities ensures safety monitoring and standardized prescribing practices across member countries, contributing to stable utilization patterns.

Competitive Landscape

Key companies operating in the global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors market include Merck & Co., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company, Sanofi, and Pfizer Inc.. These companies operate across branded and generic segments and supply multiple DPP-4 inhibitor formulations across global markets.

Recent Market Developments

• In December 2025, Lupin Limited received tentative approval from the U.S. FDA for its generic sitagliptin tablets. The approval covers 25 mg, 50 mg, and 100 mg strengths intended as equivalents to branded sitagliptin products used in the treatment of type 2 diabetes.

• In June 2025, Abbott and MSD have entered into a strategic collaboration to distribute oral anti-diabetic medications in India, including sitagliptin, the sitagliptin/metformin combination, and the extended-release formulation of sitagliptin.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By drug type
• Region Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

Competitive Landscape- Merck & Co., AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis AG, Takeda Pharmaceutical Company, Sanofi, and Pfizer Inc..

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment

By drug type

• Sitagliptin and vildagliptin
• Saxagliptin
• Linagliptin
• Gemigliptin
• Anagliptin
• Teneligliptin

Global Dipeptidyl Peptidase 4 (DPP-4) Inhibitors Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dipeptidyl-peptidase-4-inhibitors-market